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was included in the overall estimate of WTP. CONCLUSIONS:
The results from this study illustrate the value that OA patients
attribute to the reduction in GI-side effects associated with Cox-
2 selective inhibitors such as VIOXX. On average, patients were
willing to pay $A57.85 per month for a medication that specif-
ically reduced the risk of both complicated and uncomplicated
PUBs.
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OBJECTIVES: We describe pain level, medication use, potential
medication-related events, perceived medication effectiveness,
and medication switching among osteoarthritis (OA) patients.
METHODS: Patients totaling 4386 with self-reported OA com-
pleted an internet survey. Recent OA pain level was reported on
a 0–10 scale (10 = “worst possible” pain). Respondents reported
regular Rx and OTC medication use (~{!]~} 3x/wk), perceived
medication effectiveness, and frequency of 6 conditions possibly
associated with OA treatment(s) such as diarrhea, nausea/vom-
iting, heartburn, stomach pain, headache, and dizziness. Cate-
gorical frequencies were conservatively converted to continuous
variables (e.g., 1–3x a month = 1/month) to facilitate estimation.
Statistical comparisons were made using student’s t tests, X2, and
ANOVA. Logistic regression was used to identify predictors of
medication switching. RESULTS: Demographics: Mean age 55.3
years, 70.8% female, 91.4% white. Average recent OA pain was
4.9; 70.1% reported pain in 3 joints. 28.0%, 27.8%, and 32.2%
reported taking only OTC, only Rx, or both on a regular basis,
respectively. Twenty-ﬁve percent felt their OA medications were
slightly or not effective; 54.1% felt they were only moderately
effective. A total of 34.4% switched or discontinued medica-
tion(s) during the past year; 41.5% and 35.1% of these patients
cited lack of effectiveness and/or side-effects as a reason, respec-
tively. Respondents using both Rx and OTC OA medications
experienced potentially medication-related events more fre-
quently than those not taking medication. Patients who switched
OA medications reported experiencing higher recent OA pain,
GI events (compared to non-GI), pain in more than 6 joints, and
more than 3 events potentially related to medication use and
were more likely to be female (all p £ 0.05). CONCLUSIONS:
The burden of OA on patients in terms of pain, medication use,
and potential side effects is high. Only 1 in 4 patients in our
sample perceived their OA medications to be effective, and most
reported experiencing at least some OA pain despite regular
medication use.
PAR14
CONTRIBUTION OF PAIN, SITE OF PAIN AND NUMBER OF
JOINTS AFFECTED ON PRODUCTIVITY LOSS AMONG
WORKERS AND NON-WORKERS WITH OSTEOARTHRITIS
Mahajan S1, Kauf T1, Chang J2, Omar M2, Kahler K2, Schulman K1
1Duke University, Durham, NC, USA; 2Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA
OBJECTIVES: We examined productivity hours lost due to pain,
site of pain, and number of joints affected among workers and
non-workers with osteoarthritis (OA). METHODS: A total of
4386 self-reported OA patients completed an internet survey.
Respondents reported previous week’s work or daily activity
hours lost due to OA, OA pain (scale 0–10, 10 = “worst possi-
ble” pain over past 24 hours), site(s) of pain, and affected
joint(s). Impact of pain, number of affected joints, and site of
pain on total hours lost was evaluated using generalized linear
regression and including a pain level-employment interaction.
RESULTS: Demographics: mean age 55.3 years, 70.8% female,
91.4% white. Average recent OA pain was 4.9. Average hours
lost were 10.2 (SD 24.1). Non-workers reported more hours 
lost (18.2 vs. 1.7; p < 0.0001) and higher pain (5.4 vs. 4.5, 
p < 0.0001) than workers. Higher pain was associated with
increased lost hours for both groups, but more so for non-
workers (p < 0.0001). Both workers and non-workers with pain
in >7 joints lost signiﬁcantly more hours than those with fewer
affected joints (3.5 vs. 1.4 for workers, 31.6 vs. 14.1 for non-
workers, p < 0.0001). Lost hours were signiﬁcantly greater for
lower vs. upper body pain for both groups (1.5 vs. 0.5 for
workers, 10.9 vs. 5.6 for non-workers, p < 0.0001). Higher pain,
pain in >7 joints, low back pain, and pain-employment interac-
tion predicted hours lost due to OA (all p £ 0.05) after control-
ling for age, race, gender, education, employment, income, and
regular medication use. Speciﬁc joint sites did not predict lost
hours. The pain and pain-employment interaction parameters
indicate that non-workers lose more hours than workers at every
pain level and this differential increases with higher pain. CON-
CLUSIONS: Recent OA pain and the number of affected joints
but not individual pain site(s) impacted productivity. These
effects were greater for non-workers who likely have more severe
OA symptoms.
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It is well recognized that African-American (AA) patients with
knee osteoarthritis (OA) undergo total knee replacement (TKR)
at lower rates than their White (W) counterparts, OA. OBJEC-
TIVE: The purpose of this study was to evaluate the preferences
and beliefs of patients with knee OA from diverse ethnic back-
grounds in relation to TKR. METHODS: One hundred ninety-
eight patients with knee OA attending a health institution
participated in a survey; 67 were W, 66 AA and 65 Hispanic (H);
63% were female; mean age was 64.2 years. Patients were asked
if their physicians had recommended TKR, whether they had
thought about having the procedure, about their perceptions on
the beneﬁts and risks of TKR, and their potential expectations
if they were to undergo the procedure. RESULTS: A physician
had recommended TKR to 27% of AA, 15% of W and 11% of
H (p = 0.04). However, more W had considered undergoing
TKR: 42% v 30% AA and 25% H (p = 0.10); 97% of W, 85%
of AA and 75% of H reported that they would consider TKR if
their OA worsened and the procedure were recommended by
their physician (p = 0.002). Statistical differences were observed
in the perception of efﬁcacy across the groups: W were more
likely to consider TKR as a beneﬁcial procedure, and as an inter-
vention that could be helpful for them, compared to AA and H;
88% of W, 70% of AA and 57% of H had a close friend or rel-
ative who had undergone TKR (p = 0.001); these patients were
more likely to consider TKR than those who did not have rela-
tives or friends with TKR (p = 0.001). CONCLUSIONS: Ethnic
minority patients with knee OA are less likely to consider TKR,
preferences are associated with differences in perception of
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beneﬁt, and with lack of personal experiences with TKR within
their social environment.
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In February 1998, the Food and Drug Administration (FDA)
released draft Guidance for Industry for the development 
of osteoarthritis (OA) products; providing recommendations
regarding the use of patient reported outcomes (PRO) in OA
product trials and labeling. OBJECTIVES: Identify trends in
PRO measurements in clinical trials and subsequent labeling
claims for drug products indicated for OA. METHODS: The
Physician Desk Reference (PDR) was searched for “Osteoarthri-
tis” within the indication. Summary Basis for Approvals (SBA)
for drug products indicated for the treatment of OA were
obtained from the FDA website (www.fda.gov). The FDA Draft
Guidance was reviewed for recommendations on the use of
PROs. Product labels and SBAs were evaluated chronologically
based on the date of approval and observed for trends in the use
of PROs before and after the release of the FDA guidance.
RESULTS: Overall, 11 products were identiﬁed as indicated for
OA, with 9 products speciﬁcally indicated for the relief of signs
and symptoms. Review of SBAs for the six products approved
prior to the introduction of the FDA guidance revealed that four
products measured patient global assessment, four included a
patient assessment, two incorporated a patient assessment of OA
activity, and one label contained a PRO claim. After the intro-
duction of the ﬁrst FDA draft guidance, ﬁve products were
approved and four included a patient global assessment, patient
assessment of pain, and the Western Ontario and McMaster Uni-
versities Osteoarthritis Index (WOMAC) in their pivotal trials,
coinciding with the Guidance’s recommendation for efﬁcacy end-
points in OA clinical trials. All four of these products contained
PRO information in their labels, including the WOMAC. CON-
CLUSIONS: Since the introduction of the FDA guidance for OA
products, there has been an increase in proportion of OA prod-
ucts that describe PRO measurement in clinical trials and PRO
claims appearing in OA labels.
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OBJECTIVES: To characterize dosing patterns and utilization of
tumor necrosis factor-alpha (TNF-alpha) inhibitors in rheuma-
toid arthritis (RA) patients as part of a quality assurance initia-
tive on appropriate use of TNF-alpha inhibitors. METHODS:
RA patients given inﬂiximab or etanercept between January
2001 and May 2002 were identiﬁed (N = 936) using pharmacy
and medical claims. Prescribers of the affected health plan were
requested via letter to send copies of identiﬁed patients’ charts.
TNF-alpha inhibitor utilization data were abstracted from avail-
able charts. Outcomes measured included TNF-alpha inhibitor
dosing, switching, and discontinuation. This retrospective study
started prior to the compliance date of the Health Insurance
Portability and Accountability Act (HIPAA); nevertheless, it was
conducted in a manner that was compliant with HIPAA require-
ments. RESULTS: Charts were obtained for 457 (49%) patients;
369 were eligible for study enrollment (164 [44%] received
inﬂiximab, 205 [56%] received etanercept). Mean ﬁrst doses
were 3.5mg/kg (inﬂiximab) and 27.9mg (etanercept). Subse-
quent doses were 4.2mg/kg (inﬂiximab) and 25.7mg (etaner-
cept). Overall, 67.2% of inﬂiximab infusions used no more than
the number of vials expected if dosed at 3mg/kg. The inﬂiximab
cohort had a signiﬁcantly lower switch rate than the etanercept
cohort (5.2% versus 15.5%, p = 0.006). Discontinuation (i.e.,
no documentation of TNF-alpha inhibitor during the 70-day
period prior to study end date or a chart order to discontinue
TNF-alpha inhibitor) occurred among 63.3% patients receiving
etanercept and 40.0% receiving inﬂiximab (p = 0.0002). 
CONCLUSIONS: Most patients received acceptable doses of
TNF-alpha inhibitor. A minority of patients receiving either med-
ication experienced an increase in dosing. Patients receiving
inﬂiximab had lower switch and discontinue rates than patients
receiving etanercept; further research is needed to examine
reasons for this observation. These results can be used by
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OBJECTIVES: To determine whether race inﬂuences a patient’s
likelihood of being prescribed selective cyclooxygenase-2
inhibitors (COX-2s) versus other nonsteroidal anti-inﬂammatory
agents (NSAIDs) in Medicaid managed care plans (MCOs).
METHODS: All medical and prescription claims for MCO
enrollees receiving at least one prescription for a COX-2 or
NSAID between January 2000 and June 2002 were retrieved.
Selected for study were adults claiming at least one COX-2 pre-
scription or NSAID prescription with a minimum 30 days supply
after June 2000; having 60 total days of supply or more over the
study period was also required for study inclusion. The proba-
bility of being a COX-2 user was estimated as a logistic function
of patient age, gender, race, city/suburban/rural residence, and
history of rheumatoid arthritis, osteoarthritis, chronic back pain,
acute pains, gastrointestinal problems, and comorbidities (hyper-
tension, hyperlipidemia, obesity, diabetes, renal problems,
alcohol/tobacco/drug abuse, cardiovascular events). RESULTS:
Sample COX-2 users numbered 4349 and NSAID users num-
bered 13,489. Half were African-American, three-quarters were
female, and a third was over 50 years old. After adjusting for
confounders, African-American and other races were a third less
likely to be COX-2 users than Caucasians (OR, 0.66; 95% CI,
0.61–0.72). Residence in Baltimore was an additional factor
reducing COX-2 usage (OR, 0.87; 95% CI, 0.80–0.95). Gender
was not a signiﬁcant factor. Age and all clinical covariates but
diabetes was signiﬁcant predictors at the 0.05 level. CONCLU-
SION: Race signiﬁcantly affected access to COX-2 medication
in Medicaid MCOs, even after adjusting for other demographic
and clinical variables. Cost to the patient was not a factor, as the
patient copayment was $1 for any prescription.
